FDA-APPROVED FOR A SPECIFIC USE
What is PT-141 / Bremelanotide?
Bremelanotide (also known as PT-141) is a melanocortin receptor agonist. It is FDA-approved under the brand name Vyleesi specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, working through central nervous system pathways rather than vascular mechanisms.
Areas of Research Interest
- Melanocortin receptor pathway studies
- Central nervous system mechanisms of sexual desire
- Clinical trial data on HSDD treatment outcomes
- Broader melanocortin system research
Regulatory Status
Bremelanotide is FDA-approved under the brand name Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women. Uses outside of this approved indication are considered off-label and are not FDA-approved.
Educational information only. This content is not intended to diagnose, treat, cure, or prevent any disease, and does not provide guidance on personal use, dosing, or administration. Consult qualified professionals and current regulatory sources for guidance specific to your situation.